Meeting
2022 ASCO Annual Meeting
Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma: A BEACON-Neuroblastoma biomarker study.
Authors
Lucas Moreno
Division of Pediatric Oncology & Hematology, Vall d'Hebron University Hospital, Barcelona, Spain
Lucas Moreno , Rebekah Weston , Virginie Viprey , Andrei Tchirkov , Maria Corrias , Tim Lammens , Juliet Gray , Cormac Owens , Jennifer Laidler , Marion Gambart , Victoria Castel , Natasha Van Eijkelenburg , Karsten Nysom , Genevieve Laureys , Aurora Castellano , Nicolas U. Gerber , Ruth Lydia Ladenstein , Dominique Valteau Couanet , Keith Wheatley , Susan A Burchill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02308527
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10039)
DOI
10.1200/JCO.2022.40.16_suppl.10039
Abstract #
10039
Poster Bd #
254
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
First Author: Holger N. Lode
First Author: Lucas Moreno
Poster
2024 ASCO Annual Meeting
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
First Author: Olalekan O. Oluwole
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens